| Clarithromycin 500
Treatment of infectious and inflammatory diseases caused by susceptible to clarithromycin agents: infections of the upper respiratory tract and upper respiratory tract (tonzillofaringit, otitis media, acute sinusitis); infections of the lower respiratory tract (acute bronchitis, exacerbation of chronic bronchitis, community-acquired bacterial and atypical pneumonia); odontogenic infection; Skin and soft tissue infections; mycobacterial infections (M.avium complex, M.kansasii, M.marinum, M.leprae) and their prevention in AIDS patients; Helicobacter pylori eradication in patients with duodenal ulcer or gastric (only in combination therapy).
Clarithromycin 500
Specifying a history of lengthening the interval QT, ventricular fibrillation or ventricular tachycardia type "pirouette"; hypokalaemia (risk of prolongation of the QT interval); severe liver failure, to run concurrently with renal insufficiency; cholestatic jaundice / hepatitis in history, which developed in the application of clarithromycin; porphyria; I trimester of pregnancy; lactation (breastfeeding); concomitant use of clarithromycin with astemizole, cisapride, pimozide, terfenadine; with ergot alkaloids, for example ergotamine, dihydroergotamine; with midazolam oral; inhibitors of HMG-CoA reductase inhibitors (statins), which largely metabolized isoenzyme CYP3A4 (lovastatin, simvastatin) with colchicine; with ticagrelor or ranolazine; Clarithromycin 500
Hypersensitivity to clarithromycin and other macrolides.
|